These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2049687)

  • 21. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy.
    Kimball BP; Bui S; Wigle ED
    Am Heart J; 1993 Jun; 125(6):1691-7. PubMed ID: 8498312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.
    Niki K; Sugawara M; Tanino S; Iwade K; Hosoda S; Kasanuki H
    Heart Vessels; 1999; 14(2):72-81. PubMed ID: 10651183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy.
    Hongo M; Nakatsuka T; Takenaka H; Tanaka M; Watanabe N; Yazaki Y; Sekiguchi M
    Cardiology; 1996; 87(1):6-11. PubMed ID: 8631046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy.
    Minami Y; Kajimoto K; Kawana M; Hagiwara N; Sherrid MV
    Int J Cardiol; 2010 May; 141(2):195-7. PubMed ID: 19097655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptomatic obstructive hypertrophic cardiomyopathy.
    Sorajja P; Ommen SR; Nishimura RA
    Circ Cardiovasc Interv; 2013 Oct; 6(5):586-91. PubMed ID: 24129935
    [No Abstract]   [Full Text] [Related]  

  • 27. Danger of use of disopyramide in patients with hypertrophic obstructive cardiomyopathy. An electrophysiologic study.
    Miyajima S; Aizawa Y; Matsuoka A; Okabe M; Shibata A
    Jpn Heart J; 1988 Jan; 29(1):115-9. PubMed ID: 3398239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
    Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
    J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide.
    Pollick C
    N Engl J Med; 1982 Oct; 307(16):997-9. PubMed ID: 7202121
    [No Abstract]   [Full Text] [Related]  

  • 30. [Mitral valve dysplasia in a cat causing reversible left ventricular hypertrophy and dynamic outflow tract obstruction].
    Kuijpers NW; Szatmári V
    Tijdschr Diergeneeskd; 2011 May; 136(5):326-31. PubMed ID: 21614848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration.
    Pollick C; Kimball B; Henderson M; Wigle ED
    Am J Cardiol; 1988 Dec; 62(17):1248-51. PubMed ID: 3195486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.
    Fritz KI; Bhat AM
    J Perinatol; 1998; 18(1):38-44. PubMed ID: 9527943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of hypertrophic cardiomyopathy with right ventricular outflow obstruction manifested during three-year follow-up study].
    Satoh R; Okada T; Oimatsu H; Sawai K; Ogawa T; Tuchida A
    Kokyu To Junkan; 1990 Sep; 38(9):913-7. PubMed ID: 2236965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for true obstruction to left ventricular outflow in obstructive hypertrophic cardiomyopathy (muscular or hypertrophic subaortic stenosis).
    Wigle ED; Rakowski H
    Z Kardiol; 1987; 76 Suppl 3():61-8. PubMed ID: 3433876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficiency of disopyramide in hypertrophic cardiomyopathy during stress states.
    Millaire A; Goullard L; Decoulx E; de Groote P; Houdas Y; Ducloux G
    Am J Cardiol; 1992 Feb; 69(4):423-4. PubMed ID: 1734662
    [No Abstract]   [Full Text] [Related]  

  • 36. Antiarrhythmic agent cibenzoline attenuates latent obstruction in the left ventricular outflow tract of hypertrophic cardiomyopathy.
    Nomura T; Kojima A; Urakabe Y; Enomoto-Uemura S; Nishikawa S; Keira N; Matsubara H; Tatsumi T
    Int J Cardiol; 2011 May; 148(3):359-61. PubMed ID: 20888654
    [No Abstract]   [Full Text] [Related]  

  • 37. Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy.
    Teraguchi M; Ikemoto Y; Kobayashi Y
    Circ J; 2002 Jul; 66(7):709-11. PubMed ID: 12135145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of cibenzoline on biventricular pressure gradients in a pediatric patient with hypertrophic obstructive cardiomyopathy.
    Ishikawa T; Iwashima S; Ohzeki T
    Pediatr Cardiol; 2010 Jul; 31(5):707-10. PubMed ID: 20140606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hypertrophic cardiomyopathy in childhood: studies of the clinical picture and course].
    Schmaltz AA; Sieverding L; Barth H; Steil E; Apitz J
    Z Kardiol; 1986 Jul; 75(7):435-40. PubMed ID: 3765768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Left ventricular outflow obstruction due to accessory mitral tissue].
    Chorro FJ; Losada A; Muñoz J; Cortina J; Monmeneu JV; Ibáñez M; Martínez Mas ML; López Merino V
    Rev Esp Cardiol; 1993 Jun; 46(6):392-5. PubMed ID: 8316708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.